Company: ATRA
Filing Date: 2025-01-21
Form Type: 8-K
Source: 0000950170-25-006992
Chunk: 0

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-01-21
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01 Other Events.

On January 21, 2025, Atara Biotherapeutics, Inc., (the “ Company”) issued a press release announcing that the U. S. Food and Drug Administration (the “ FDA”) has placed a clinical hold on Atara’s active Investigational New Drug (IND) applications. These INDs include the EBVALLOTM(tabelecleucel) program as monotherapy treatment for adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), as well as ATA3219, an allogeneic CD19-targeted CAR-T therapy, for the treatment of non-Hodgkin’s lymphoma and systemic lupus erythematosus. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference into this Item 8.01.

Item 9.01 Financial Statements and Exhibits.